Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
High levels of 25-hydroxyvitamin D (top quintile) were associated with a reduced multiple sclerosis risk (odds ratio 0.68, 95% confidence interval 0.50 to 0.93).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this nested case: control study we accessed five Swedish microbiological biobanks associated with university hospitals in Umeå, Örebro, Göteborg, Skåne and Linköping and one biobank from the Public Health Agency of Sweden (PHAS), to obtain serum or plasma from a total of 670 individuals who later developed RRMS and 670 controls matched for biobank and sex, and with decreasing priority for date of sampling and age.
Source: Methods.
All samples from MS patients were collected 8 years prior to symptom onset (in median) and all participants were below 40 years of age at the time of sampling.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Full studies
High serum concentration of vitamin D may protect against multiple sclerosis
Case-control study · Multiple Sclerosis Journal: Experimental, Translational and Clinical · 2019
Original publication title
High serum concentration of vitamin D may protect against multiple sclerosis
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Investigate the 25-hydroxyvitamin D association with multiple sclerosis and test if this association is age dependent.
Source: ObjectiveStudy methods
What methods does the paper describe?
Case ascertainment
In this nested case: control study we accessed five Swedish microbiological biobanks associated with university hospitals in Umeå, Örebro, Göteborg, Skåne and Linköping and one biobank from the Public Health Agency of Sweden (PHAS), to obtain serum or plasma from a total of 670 individuals who later developed RRMS and 670 controls matched for biobank and sex, and with decreasing priority for date of sampling and age. These biobanks contain remainders from serological analysis in routine clinical practice. Cases were identified either through crosslinking with the Swedish MS registry (www.neuroreg.se) or a local MS/possible MS database, and a total of 665 complete sets of cases and controls were included in the final analysis (see Supplementary Figure 1).
All samples from MS patients were collected 8 years prior to symptom onset (in median) and all participants were below 40 years of age at the time of sampling. The absolute mean difference between cases and controls was 6 days for the date of sampling and 152 days for the age at sampling.
Laboratory analysis
The concentration of 25(OH)D3 was analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS) as described previously.7 Samples for matched cases and controls were analysed immediately after each other and in random order, and technicians were blinded to case: control status.
Statistical analysis
We modelled 25(OH)D3 levels as quintiles, derived from the distribution among controls, separately for each biobank as the levels differed significantly between them (Kruskal: Wallis test P ≤ 0.001). These quintile assignments were used in a pooled analysis that included all individuals. The Mann: Whitney U-test was used to test differences between groups, odds ratios (ORs) and P for trend over quintiles were calculated using conditional logistic regression. Age was stratified into three groups based on the age at sample draw, less than 20, 20 to 29 and 30 to 39 years of age.
If a case: control set was on different sides of an age cut-off they were assigned to either the youngest or oldest group containing either a case or control, in order to increase power in the smaller groups. IBM SPSS statistics version 23 (IBM Corporation, New York, NY, USA) was used for statistical analysis.
Ethical considerations
This study was approved by a local regional ethical review board in Umeå (2011-198-31M). No written informed consent was required for participation.
Discussion
Although cases and controls did not significantly differ in median levels of 25(OH)D and there was no significant trend over quintiles, we did find a decreased MS risk among individuals with concentrations in the top quintile. These findings suggest that there may exist a threshold located within the higher range of 25(OH)D levels (cut-off 70 to 82 nmol/L in the six biobanks) above which the effect of 25(OH)D modulates MS risk. This is in line with the findings of one earlier study using 75 nmol/L as a cut-off.2 Data from the currently largest pre-symptomatic study, performed in a Finnish maternity cohort,3 seem to indicate that seasonally corrected levels above 50 nmol/L are protective when compared to less than 30 nmol/L.
In that study, 6% of cases and 7.5% of controls were above 50 nmol/L, compared to 54.6% and 56.1% in our study. Although we found higher vitamin D levels, they are in line with previously published population-based studies in our region.8 Differences in methodology, including 25(OH)D assay and the use of seasonal correction of multiple samples from each individual in the Finnish study, may explain some of the differences in absolute 25(OH)D and a direct comparison between the studies may therefore be inappropriate.9
A strength of our study is the relatively large number of individuals below 20 years of age, enabling comparisons of different age strata. These analyses did not yield any significant findings, however, but the effect sizes converge with earlier studies.1,2 Furthermore, this is to our knowledge the first study applying the gold standard method LC-MS/MS.
The main limitation in our study is that the samples came from six unique biobanks, with different pre-analytical procedures and geographically distinct catchment areas, both of which may influence the results as well as provide a geographical explanation of why serum concentrations of vitamin D differed between biobanks. To minimise this, we matched cases and controls from the same biobank and defined quintiles separately for each biobank. Pooling of site-specific quintiles has been used previously10 and enabled analysis of the total cohort by applying a similar relative cut-off (i.e. top quintile), despite the biobanks representing a heterogenous material.
Also, we did not have access to data on race/ethnicity and the results may therefore not be generalisable to other populations. In addition, the retrospective compilation of data may have implicated other biases affecting the results that we have not considered.
In conclusion, our results further support the hypothesis that relatively higher 25(OH)D concentrations may protect against the development of MS but not that the effect is stronger among young individuals.
Source: Discussion Source: Discussion Source: Discussion Source: DiscussionSupplemental Material
MSO892291 Supplemental Material: Supplemental material for High serum concentration of vitamin D may protect against multiple sclerosis
Click here for additional data file.
Supplemental material, MSO892291 Supplemental Material for High serum concentration of vitamin D may protect against multiple sclerosis by Martin Biström Lucia Alonso-Magdalena Oluf Andersen, Daniel Jons, Martin Gunnarsson Magnus Vrethem Johan Hultdin Peter Sundström in Multiple Sclerosis Journal: Experimental, Translational and Clinical
Results
Median 25(OH)D3 did not differ between cases and controls (Table 1). Being in the top 25(OH)D3 quintile was significantly associated with a decreased risk of MS in the total cohort (OR 0.68, 95% confidence interval (CI) 0.50 to 0.93) (Table 2). A sensitivity analysis excluding the PHAS biobank, which had higher levels compared to the others, yielded an OR of 0.69 (95% CI 0.49 to 0.97) when using the median cut-off for the remaining biobanks (72 nmol/L). Subgroup analyses in different age strata were not significant and we found no trend over 25(OH)D3 quintiles.
Characteristics of cases and controls.
| n | Cases | n | Controls | P value | |
|---|---|---|---|---|---|
| Sex (M/F) | 665 | 16.2/83.8% | 665 | 16.2/83.8% | |
| Age at sampling, years | 665 | 25 (21 to 29) | 665 | 25 (21 to 29) | |
| Age at disease onset, years | 665 | 33 (28 to 40) | n.a. | ||
| Time from sampling until disease onset, years | 665 | 8 (4 to 13) | n.a. | ||
| Biobank: latitude | |||||
| Umeå: 63°N | 102 | 15.3% | 102 | 15.3% | |
| Vitamin D3 | 47 (37 to 61) | 53 (39 to 68) | 0.07 | ||
| Samples collected between, years | 1976 to 2007 | 1976 to 2007 | |||
| PHAS: n.a. | 137 | 20.6% | 137 | 20.6% | |
| Vitamin D3 | 59 (43 to 75) | 56 (39 to 77) | 0.64 | ||
| Samples collected between, years | 1972 to 2001 | 1972 to 2001 | |||
| Örebro: 59°N | 29 | 4.3% | 29 | 4.3% | |
| Vitamin D3 | 52 (41 to 63) | 50 (36 to 70) | 0.96 | ||
| Samples collected between, years | 1994 to 2008 | 1994 to 2008 | |||
| Göteborg: 57°N | 47 | 7.1% | 47 | 7.1% | |
| Vitamin D3 | 56 (41 to 65) | 55 (44 to 67) | 0.97 | ||
| Samples collected between, years | 1995 to 2009 | 1995 to 2009 | |||
| Skåne: 55°N | 311 | 46.8% | 311 | 46.8% | |
| Vitamin D3 | 52 (41 to 68) | 52 (40 to 70) | 0.93 | ||
| Samples collected between, years | 1977 to 2007 | 1977 to 2007 | |||
| Linköping: 58°N | 39 | 5.9% | 39 | 5.9% | |
| Vitamin D3 | 43 (30 to 57) | 51 (32 to 61) | 0.33 | ||
| Samples collected between, years | 1993 to 2009 | 1993 to 2009 | |||
| All subjects | 665 | 665 | |||
| Vitamin D3 | 53 (40 to 67) | 53 (39 to 70) | 0.50 | ||
| Age group <20 years | 142 | 142 | |||
| Vitamin D3 | 49 (38 to 64) | 51 (39 to 67) | 0.47 | ||
| Age group 20 to 29 years | 374 | 374 | |||
| Vitamin D3 | 53 (41 to 67) | 53 (39 to 71) | 0.73 | ||
| Age group 30 to 39 years | 149 | 149 | |||
| Vitamin D3 | 55 (41 to 72) | 56 (42 to 73) | 0.83 |
PHAS: Public Health Agency of Sweden.
Median (25th: 75th percentiles) for continuous variables and percentages for proportions.
Vitamin D concentrations expressed as nmol/L.
Associations of vitamin D3 concentration and MS stratified by biobank and age.
| Vitamin D categories | Cut-off nmol/L | Number of (%) | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| Cases | Controls | |||||
| Biobank | ||||||
| Umeå | Quintile 1 to 4 | 38, 48, 59 | 90 (88.2) | 81 (79.4) | ref | |
| Quintile 5 | ≥73 | 12 (11.8) | 21 (20.6) | 0.47 | 0.20 to 1.1 | |
| PHAS | Quintile 1 to 4 | 37, 50, 63 | 114 (83.2) | 109 (79.6) | ref | |
| Quintile 5 | ≥82 | 23 (16.8) | 28 (20.4) | 0.75 | 0.38 to 1.5 | |
| Örebro | Quintile 1 to 4 | 35, 48, 60 | 26 (89.7) | 23 (79.3) | ref | |
| Quintile 5 | ≥72 | 3 (10.3) | 6 (20.7) | 0.40 | 0.08 to 2.1 | |
| Göteborg | Quintile 1 to 4 | 41, 50, 59 | 41 (87.2) | 37 (78.7) | ref | |
| Quintile 5 | ≥71 | 6 (12.8) | 10 (21.3) | 0.43 | 0.11 to 1.7 | |
| Skåne | Quintile 1 to 4 | 38, 47, 58 | 252 (81.0) | 248 (79.7) | ref | |
| Quintile 5 | ≥73 | 59 (19.0) | 63 (20.3) | 0.90 | 0.58 to 1.4 | |
| Linköping | Quintile 1 to 4 | 27, 42, 55 | 37 (94.9) | 31 (79.5) | ref | |
| Quintile 5 | ≥70 | 2 (5.1) | 8 (20.5) | 0.25 | 0.05 to 1.2 | |
| All | Quintile 1 to 4 | 560 (84.2) | 529 (79.5) | ref | ||
| Quintile 5 | 105 (15.8) | 136 (20.5) | 0.68 | 0.50 to 0.93 | ||
| Alla | Quintile 1 | 134 (20.1) | 133 (20.0) | ref | ||
| Quintile 2 | 142 (21.4) | 133 (20.0) | 1.1 | 0.77 to 1.5 | ||
| Quintile 3 | 131 (19.7) | 130 (19.5) | 0.99 | 0.71 to 1.4 | ||
| Quintile 4 | 153 (23.0) | 133 (20.0) | 1.1 | 0.78 to 1.6 | ||
| Quintile 5 | 105 (15.8) | 136 (20.5) | 0.72 | 0.49 to 1.1 | ||
| Age group | ||||||
| <20 | Quintile 1 to 4 | 126 (88.7) | 118 (83.1) | ref | ||
| Quintile 5 | 16 (11.3) | 24 (16.9) | 0.60 | 0.29 to 1.2 | ||
| 20 to 29 | Quintile 1 to 4 | 313 (83.7) | 297 (79.4) | ref | ||
| Quintile 5 | 61 (16.3) | 77 (20.6) | 0.70 | 0.46 to 1.1 | ||
| 30 to 39 | Quintile 1 to 4 | 121 (81.2) | 114 (76.5) | ref | ||
| Quintile 5 | 28 (18.8) | 35 (23.5) | 0.72 | 0.39 to 1.3 | ||
MS: multiple sclerosis; OR: odds ratio; CI: confidence interval; PHAS: Public Health Agency of Sweden.
aIn the total cohort, P for trend over quintiles was 0.24.
Abstract: Conclusion
These findings further support a role for vitamin D in MS aetiology.
Source: ConclusionAuthors’ abstract
Background
High 25-hydroxyvitamin D concentrations have been associated with a reduced risk of multiple sclerosis, with indications of a stronger effect among young individuals.
Objective
Investigate the 25-hydroxyvitamin D association with multiple sclerosis and test if this association is age dependent.
Methods
Prospectively drawn blood samples from individuals later developing relapsing: remitting multiple sclerosis and controls matched for biobank, sex, age and date of sampling, were analysed with liquid chromatography tandem mass spectrometry.
Results
High levels of 25-hydroxyvitamin D (top quintile) were associated with a reduced multiple sclerosis risk (odds ratio 0.68, 95% confidence interval 0.50 to 0.93).
Conclusion
These findings further support a role for vitamin D in MS aetiology.
Read the full paper
Introduction
Higher serum concentrations of 25-hydroxyvitamin D (25(OH)D) have repeatedly been associated with a decreased risk of multiple sclerosis (MS) development in nested case: control studies1Not reported3 with one study showing a larger effect before 20 years of age.1 Additional support for a causal role of vitamin D in MS aetiopathogenesis comes from Mendelian randomisation studies4,5 but this subject remains controversial.6
In this study we aimed to test the hypothesis that high 25(OH)D concentrations reduce the risk of developing MS, with a more pronounced effect among young individuals, by comparing blood samples from healthy controls to samples from individuals who later developed relapsing: remitting multiple sclerosis (RRMS). To achieve these goals, we accessed six Swedish biobanks specifically chosen because they include plasma or serum drawn at a young age.
Materials and methods
Case ascertainment
In this nested case: control study we accessed five Swedish microbiological biobanks associated with university hospitals in Umeå, Örebro, Göteborg, Skåne and Linköping and one biobank from the Public Health Agency of Sweden (PHAS), to obtain serum or plasma from a total of 670 individuals who later developed RRMS and 670 controls matched for biobank and sex, and with decreasing priority for date of sampling and age. These biobanks contain remainders from serological analysis in routine clinical practice. Cases were identified either through crosslinking with the Swedish MS registry (www.neuroreg.se) or a local MS/possible MS database, and a total of 665 complete sets of cases and controls were included in the final analysis (see Supplementary Figure 1).
All samples from MS patients were collected 8 years prior to symptom onset (in median) and all participants were below 40 years of age at the time of sampling. The absolute mean difference between cases and controls was 6 days for the date of sampling and 152 days for the age at sampling.
Laboratory analysis
The concentration of 25(OH)D3 was analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS) as described previously.7 Samples for matched cases and controls were analysed immediately after each other and in random order, and technicians were blinded to case: control status.
Statistical analysis
We modelled 25(OH)D3 levels as quintiles, derived from the distribution among controls, separately for each biobank as the levels differed significantly between them (Kruskal: Wallis test P ≤ 0.001). These quintile assignments were used in a pooled analysis that included all individuals. The Mann: Whitney U-test was used to test differences between groups, odds ratios (ORs) and P for trend over quintiles were calculated using conditional logistic regression. Age was stratified into three groups based on the age at sample draw, less than 20, 20 to 29 and 30 to 39 years of age.
If a case: control set was on different sides of an age cut-off they were assigned to either the youngest or oldest group containing either a case or control, in order to increase power in the smaller groups. IBM SPSS statistics version 23 (IBM Corporation, New York, NY, USA) was used for statistical analysis.
Ethical considerations
This study was approved by a local regional ethical review board in Umeå (2011-198-31M). No written informed consent was required for participation.
Results
Median 25(OH)D3 did not differ between cases and controls (Table 1). Being in the top 25(OH)D3 quintile was significantly associated with a decreased risk of MS in the total cohort (OR 0.68, 95% confidence interval (CI) 0.50 to 0.93) (Table 2). A sensitivity analysis excluding the PHAS biobank, which had higher levels compared to the others, yielded an OR of 0.69 (95% CI 0.49 to 0.97) when using the median cut-off for the remaining biobanks (72 nmol/L). Subgroup analyses in different age strata were not significant and we found no trend over 25(OH)D3 quintiles.
Characteristics of cases and controls.
| n | Cases | n | Controls | P value | |
|---|---|---|---|---|---|
| Sex (M/F) | 665 | 16.2/83.8% | 665 | 16.2/83.8% | |
| Age at sampling, years | 665 | 25 (21 to 29) | 665 | 25 (21 to 29) | |
| Age at disease onset, years | 665 | 33 (28 to 40) | n.a. | ||
| Time from sampling until disease onset, years | 665 | 8 (4 to 13) | n.a. | ||
| Biobank: latitude | |||||
| Umeå: 63°N | 102 | 15.3% | 102 | 15.3% | |
| Vitamin D3 | 47 (37 to 61) | 53 (39 to 68) | 0.07 | ||
| Samples collected between, years | 1976 to 2007 | 1976 to 2007 | |||
| PHAS: n.a. | 137 | 20.6% | 137 | 20.6% | |
| Vitamin D3 | 59 (43 to 75) | 56 (39 to 77) | 0.64 | ||
| Samples collected between, years | 1972 to 2001 | 1972 to 2001 | |||
| Örebro: 59°N | 29 | 4.3% | 29 | 4.3% | |
| Vitamin D3 | 52 (41 to 63) | 50 (36 to 70) | 0.96 | ||
| Samples collected between, years | 1994 to 2008 | 1994 to 2008 | |||
| Göteborg: 57°N | 47 | 7.1% | 47 | 7.1% | |
| Vitamin D3 | 56 (41 to 65) | 55 (44 to 67) | 0.97 | ||
| Samples collected between, years | 1995 to 2009 | 1995 to 2009 | |||
| Skåne: 55°N | 311 | 46.8% | 311 | 46.8% | |
| Vitamin D3 | 52 (41 to 68) | 52 (40 to 70) | 0.93 | ||
| Samples collected between, years | 1977 to 2007 | 1977 to 2007 | |||
| Linköping: 58°N | 39 | 5.9% | 39 | 5.9% | |
| Vitamin D3 | 43 (30 to 57) | 51 (32 to 61) | 0.33 | ||
| Samples collected between, years | 1993 to 2009 | 1993 to 2009 | |||
| All subjects | 665 | 665 | |||
| Vitamin D3 | 53 (40 to 67) | 53 (39 to 70) | 0.50 | ||
| Age group <20 years | 142 | 142 | |||
| Vitamin D3 | 49 (38 to 64) | 51 (39 to 67) | 0.47 | ||
| Age group 20 to 29 years | 374 | 374 | |||
| Vitamin D3 | 53 (41 to 67) | 53 (39 to 71) | 0.73 | ||
| Age group 30 to 39 years | 149 | 149 | |||
| Vitamin D3 | 55 (41 to 72) | 56 (42 to 73) | 0.83 |
PHAS: Public Health Agency of Sweden.
Median (25th: 75th percentiles) for continuous variables and percentages for proportions.
Vitamin D concentrations expressed as nmol/L.
Associations of vitamin D3 concentration and MS stratified by biobank and age.
| Vitamin D categories | Cut-off nmol/L | Number of (%) | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| Cases | Controls | |||||
| Biobank | ||||||
| Umeå | Quintile 1 to 4 | 38, 48, 59 | 90 (88.2) | 81 (79.4) | ref | |
| Quintile 5 | ≥73 | 12 (11.8) | 21 (20.6) | 0.47 | 0.20 to 1.1 | |
| PHAS | Quintile 1 to 4 | 37, 50, 63 | 114 (83.2) | 109 (79.6) | ref | |
| Quintile 5 | ≥82 | 23 (16.8) | 28 (20.4) | 0.75 | 0.38 to 1.5 | |
| Örebro | Quintile 1 to 4 | 35, 48, 60 | 26 (89.7) | 23 (79.3) | ref | |
| Quintile 5 | ≥72 | 3 (10.3) | 6 (20.7) | 0.40 | 0.08 to 2.1 | |
| Göteborg | Quintile 1 to 4 | 41, 50, 59 | 41 (87.2) | 37 (78.7) | ref | |
| Quintile 5 | ≥71 | 6 (12.8) | 10 (21.3) | 0.43 | 0.11 to 1.7 | |
| Skåne | Quintile 1 to 4 | 38, 47, 58 | 252 (81.0) | 248 (79.7) | ref | |
| Quintile 5 | ≥73 | 59 (19.0) | 63 (20.3) | 0.90 | 0.58 to 1.4 | |
| Linköping | Quintile 1 to 4 | 27, 42, 55 | 37 (94.9) | 31 (79.5) | ref | |
| Quintile 5 | ≥70 | 2 (5.1) | 8 (20.5) | 0.25 | 0.05 to 1.2 | |
| All | Quintile 1 to 4 | 560 (84.2) | 529 (79.5) | ref | ||
| Quintile 5 | 105 (15.8) | 136 (20.5) | 0.68 | 0.50 to 0.93 | ||
| Alla | Quintile 1 | 134 (20.1) | 133 (20.0) | ref | ||
| Quintile 2 | 142 (21.4) | 133 (20.0) | 1.1 | 0.77 to 1.5 | ||
| Quintile 3 | 131 (19.7) | 130 (19.5) | 0.99 | 0.71 to 1.4 | ||
| Quintile 4 | 153 (23.0) | 133 (20.0) | 1.1 | 0.78 to 1.6 | ||
| Quintile 5 | 105 (15.8) | 136 (20.5) | 0.72 | 0.49 to 1.1 | ||
| Age group | ||||||
| <20 | Quintile 1 to 4 | 126 (88.7) | 118 (83.1) | ref | ||
| Quintile 5 | 16 (11.3) | 24 (16.9) | 0.60 | 0.29 to 1.2 | ||
| 20 to 29 | Quintile 1 to 4 | 313 (83.7) | 297 (79.4) | ref | ||
| Quintile 5 | 61 (16.3) | 77 (20.6) | 0.70 | 0.46 to 1.1 | ||
| 30 to 39 | Quintile 1 to 4 | 121 (81.2) | 114 (76.5) | ref | ||
| Quintile 5 | 28 (18.8) | 35 (23.5) | 0.72 | 0.39 to 1.3 | ||
MS: multiple sclerosis; OR: odds ratio; CI: confidence interval; PHAS: Public Health Agency of Sweden.
aIn the total cohort, P for trend over quintiles was 0.24.
Discussion
Although cases and controls did not significantly differ in median levels of 25(OH)D and there was no significant trend over quintiles, we did find a decreased MS risk among individuals with concentrations in the top quintile. These findings suggest that there may exist a threshold located within the higher range of 25(OH)D levels (cut-off 70 to 82 nmol/L in the six biobanks) above which the effect of 25(OH)D modulates MS risk. This is in line with the findings of one earlier study using 75 nmol/L as a cut-off.2 Data from the currently largest pre-symptomatic study, performed in a Finnish maternity cohort,3 seem to indicate that seasonally corrected levels above 50 nmol/L are protective when compared to less than 30 nmol/L.
In that study, 6% of cases and 7.5% of controls were above 50 nmol/L, compared to 54.6% and 56.1% in our study. Although we found higher vitamin D levels, they are in line with previously published population-based studies in our region.8 Differences in methodology, including 25(OH)D assay and the use of seasonal correction of multiple samples from each individual in the Finnish study, may explain some of the differences in absolute 25(OH)D and a direct comparison between the studies may therefore be inappropriate.9
A strength of our study is the relatively large number of individuals below 20 years of age, enabling comparisons of different age strata. These analyses did not yield any significant findings, however, but the effect sizes converge with earlier studies.1,2 Furthermore, this is to our knowledge the first study applying the gold standard method LC-MS/MS.
The main limitation in our study is that the samples came from six unique biobanks, with different pre-analytical procedures and geographically distinct catchment areas, both of which may influence the results as well as provide a geographical explanation of why serum concentrations of vitamin D differed between biobanks. To minimise this, we matched cases and controls from the same biobank and defined quintiles separately for each biobank. Pooling of site-specific quintiles has been used previously10 and enabled analysis of the total cohort by applying a similar relative cut-off (i.e. top quintile), despite the biobanks representing a heterogenous material.
Also, we did not have access to data on race/ethnicity and the results may therefore not be generalisable to other populations. In addition, the retrospective compilation of data may have implicated other biases affecting the results that we have not considered.
In conclusion, our results further support the hypothesis that relatively higher 25(OH)D concentrations may protect against the development of MS but not that the effect is stronger among young individuals.
Supplemental Material
MSO892291 Supplemental Material: Supplemental material for High serum concentration of vitamin D may protect against multiple sclerosis
Click here for additional data file.
Supplemental material, MSO892291 Supplemental Material for High serum concentration of vitamin D may protect against multiple sclerosis by Martin Biström Lucia Alonso-Magdalena Oluf Andersen, Daniel Jons, Martin Gunnarsson Magnus Vrethem Johan Hultdin Peter Sundström in Multiple Sclerosis Journal: Experimental, Translational and Clinical
Acknowledgements
The authors would like to thank Staffan Lundstedt for performing the biochemical analysis.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: MB, OA, DJ, MG, JH and PS report no conflict of interest. LAM has received speaking fees from Merck-Serono and served on advisory boards for Merck-Serono and Biogen. MV has received honoraria for lectures from Genzyme and for advisory boards from Roche and Novartis.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this work was supported by the Swedish Research Council (2015-02419) and through a regional agreement between Umeå University and Västerbotten County Council (ALF) (RV-751881).
ORCID iDs
Martin Biström https://orcid.org/0000-0003-3994-2305 Johan Hultdin https://orcid.org/0000-0002-9599-0961 Peter Sundström https://orcid.org/0000-0003-3552-1861
References
Publication and source details
Original title: High serum concentration of vitamin D may protect against multiple sclerosis
Martin Biström; Lucia Alonso-Magdalena; Oluf Andersen; Daniel Jons; Martin Gunnarsson; Magnus Vrethem; Johan Hultdin; Peter Sundström
Multiple Sclerosis Journal: Experimental, Translational and Clinical · 2019
Umeå University, Department of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå, Sweden.martin.bistrom@umu.se© The Author(s) 20192019SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenseshttps://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Vetenskapsrådethttps://doi.org/10.13039/5011000043592015-02419Regional agreement between Umeå University and Västerbotten County Council (ALF)RV-751881Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T18:34:56.033498+00:00
DOI: 10.1177/2055217319892291 · PMC6900627